BioSpace News Archive

In recent years, AI-fueled drug discovery programs have risen dramatically, particularly in regard to rare diseases.

The U.S. Attorney’s Office for Massachusetts charged Ishtiaq Ali Saaem, 37, with obstruction of justice for lying about his attempts to acquire 100 castor bean packets in order to develop the bioterror poison ricin. The acquisition was not recent, it took place on June 24, 2015.

To support the development of immunodiagnostic assay, Sino Biological has successfully generated biologically active and stable Spike and NP proteins of SARS-CoV-2.

Responds to Intent to Nominate Directors from Sonic Fund Sonic’s Attempt to Control the Board Not in the Best Interests of Adverum or the Company’s Stockholders

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that it will host a conference call on March 25, 2021 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2020.

Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in hemoglobin levels and showed improvements in key clinical outcomes

Sotera Health Company announced the pricing of its secondary offering of 25,000,000 shares of its common stock at a price to the public of $27.00 per share.

Nordic Nanovector ASA announces the appointment of Peter L. Braun as Chief Executive Officer.

Company expects to complete merger with Longevity Acquisition Corporation and its American Depositary Shares to be admitted to trading on NASDAQ on 22 March 2021

More than 40 preclinical studies have found that Lixte’s lead drug candidate LB-100 increases the anti-tumor activity of chemotherapy, radiotherapy and immunotherapy without increasing toxicity